Alimera Sciences, Inc. announced the appointment of pharma financial veteran Russell L. Skibsted, as Senior Vice President and Chief Financial Officer, effective January 9, 2023. Mr. Skibsted is a seasoned pharma executive with nearly 30 years of experience in financial management, global business development, capital raises, investor relations, and operations. He has worked with a variety of both public and private life sciences companies at all stages of development. Prior to joining Alimera, he served as Executive Vice President, CFO and Chief Business Officer at Rockwell Medical, a public company providing hemodialysis products.

Previously, Mr. Skibsted served as CFO of BioTime, Inc., which he joined in 2015, where he also performed the role of CFO at various times for several of BioTime's public and private subsidiaries, including Agex Therapeutics, OncoCyte Corporation, and Asterias Biotherapeutics, Inc. Prior to BioTime, Mr. Skibsted served as CFO or Chief Business Officer for several public and private life science companies, including Aeolus Pharmaceuticals, Spectrum Pharmaceuticals and Hana Biosciences. He has also acted as a consulting CFO to various life science companies when he was the Managing Director of RSL Ventures. Earlier in his career, Mr. Skibsted held roles as Portfolio Management Partner and CFO at Asset Management Company, one of the oldest and most respected venture capital firms in Silicon Valley, and Vice President for GE Capital Services Structured Finance Group.

Mr. Skibsted holds a B.A. in Economics from Claremont McKenna College and an M.B.A. from the Stanford Graduate School of Business.